Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

Case History and Presentation 
After 4 weeks of therapy with tralokinumab 300 mg every 2 weeks, Jeremy reports a noticeable reduction in itching, with his Pruritus NRS decreasing from 8/10 to 4/10. His EASI score improves from 29 to 18, indicating reduced severity and extent of lesions. He expresses improved emotional well-being and reports better sleep as a result of reduced nighttime itching.

At this point, Jeremy is curious about maintaining these improvements and achieving further progress in managing his AD.

Based on Jeremy’s response at 4 weeks, which of the following is the next most appropriate step in his treatment plan?